Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIDOC: HCQ + Azithromycin in COVID-19 Pneumonia
NCT04345861Phase 3Terminated
- Sponsor
- CHU Montpellier
- Start
- Apr 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azithromycin in COVID-19 pneumonia (2 arms), sponsored by CHU Montpellier. Primary endpoint: Time to clinical improvement of at least 1 level on the ordinal scale. Started Apr 2020; status: terminated.
02
Drugs
azithromycin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04345861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04345861.